Therapeutic Area
Drug: Indication (Target)
Preclinical
Phase I
Phase II
Phase III
Anticipated Milestones
Anticipated Milestones
Enroll patients into Phase III AAV study

Initiate clinical endpoint study in aHUS in 2017

Initiate clinical endpoint study in C3G in 1H 2017

Initiate clinical endpoint study in FSGS in 1H 2017

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones
Vifor Pharma has future development option
Anticipated Milestones
Report Pancreatic Cancer PFS results early 1Q 2017

Initiate combination checkpoint inhibitor trial in 2017

Drug: Indication (Target)
Pre
PI
PII
PIII
CCX354: Rheumatoid Arthritis/Myeloma Bone Metastasis (CCR1)
Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

CCR1 CCX354 Completed Phase IIa

Progress in TH17 Disease

* also known as CCX282 or Traficet-EN.